Author: admin
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
DURHAM, North Carolina, USA, July 18, 2019 – – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary...
Precision BioSciences Appoints Dario Scimeca as General Counsel
DURHAM, North Carolina, USA, June 12, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS®...
Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer
DURHAM, North Carolina, USA, May 14, 2019 – Precision BioSciences (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome...
Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
DURHAM, North Carolina, May 09, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary...
Precision BioSciences Reports First Quarter 2019 Financial Results
DURHAM, North Carolina, USA, April 29, 2019 – Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its proprietary...
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
DURHAM, North Carolina, April 24, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS®...
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
First NHL patient treated with allogeneic CAR T in US-based trial DURHAM, North Carolina, April 17, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company...
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
DURHAM, North Carolina, April 1, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...
Precision BioSciences Announces Pricing of Initial Public Offering
DURHAM, North Carolina, USA, March 28, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...
Raymond Schinazi Joins Precision BioSciences Board of Directors
DURHAM, North Carolina, USA, March 14, 2019 –Precision BioSciences (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing...
Precision BioSciences Enters Into Private Convertible Note Financing
DURHAM, North Carolina, USA, March 9, 2019 – Precision BioSciences (“Precision” or the “Company”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS...
Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle
DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD,...
Science Article About the Quest to Cure HBV Brings Context to Precision BioSciences Collaboration With Gilead
Precision BioSciences is pleased to be part of this important feature story from Science Magazine: Forgotten No More – A long-overlooked scourge of millions, hepatitis B is in the crosshairs...
Precision BioSciences Receives the 2018 SEBIO Venture Funding Award
DURHAM, North Carolina, USA, November 15, 2018 – Precision BioSciences announced today that it has been recognized as the recipient of the 2018 Southeast BIO (SEBIO) Venture Funding Award. Abid...
Precision BioSciences and MaxCyte Enter Into Clinical and Commercial License Agreement
Precision BioSciences is pleased to be working with MaxCyte. Read more about our clinical and commercial license agreement to use the MaxCyte electroporation system for non-viral delivery of genome...